People · Operator
Named in public records as an officer, director or promoter · active 2012–2025 · Biotechnology, Pharmaceuticals, Pharma, Other Health Care, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aura Biosciences, Inc. | — | Biotechnology | Series C | $198.2M | $2.5B | 2012 |
| CeleCor Therapeutics, Inc. | — | Biotechnology | Series C | $71.5M | $993.8M | 2017 |
| Amylyx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $65.1M | $1.0B | 2014 |
| Artax Biopharma, Inc. | — | Biotechnology | Series B | $48.0M | $75.7M | 2013 |
| Zetagen Therapeutics, Inc. | — | Pharmaceuticals | Series A | $26.1M | $36.5M | 2017 |
| Vigeo Therapeutics, Inc. | — | Biotechnology | Series A | $17.6M | $195.0M | 2015 |
| Pulmoqune Therapeutics, Inc. | — | Pharma | Series A | $5.5M | $170.3M | 2020 |
| cystetic Medicines, Inc. | — | Other Health Care | Series A | $5.0M | $88.3M | 2020 |
| Deepbiome Therapeutics, Inc. | — | Pharma | Seed | $2.5M | $95.3M | 2019 |
| INTICA Biomedical, Inc. | — | Biotechnology | Pre-Seed | $1.6M | $54.9M | 2012 |
| Verispellis Skis & Snowboards Inc | — | Other Technology | Pre-Seed | $272K | $11.5M | 2018 |
Peter B. Finn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter B. Finn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Casper Breum | 2 | 5 |
| Alan Walts | 2 | 3 |
| Robert Hillman | 2 | 3 |
| Javier Garcia | 2 | 3 |
| Casper E. Breum | 2 | 2 |
| David Johnson | 1 | 35 |
| Isaac Cheng | 1 | 9 |
| Joshua Cohen | 1 | 8 |
| Jason Dinges | 1 | 8 |
| Stephanie O'Brien | 1 | 7 |
| Raj Parekh | 1 | 5 |
| Peter Finn | 1 | 5 |
| Gino Santini | 1 | 5 |
| Lawrence C. Best | 1 | 4 |
| Christine Bunt | 1 | 4 |
| Alan E. Walts | 1 | 3 |
| Gino W. Santini | 1 | 3 |
| Art Pappas | 1 | 3 |
| Pedro Granadillo | 1 | 3 |
| Peter Wirth | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.